A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of unresectable, locally advanced or metastatic neuroendocrine neoplasms in China

#4342

Introduction: The incidence of NENs is on the rise. In NECs, research on surufatinib is still scarce.

Aim(s): We retrospectively analysed the efficacy and safety of targeted therapy with surufatinib in patients with locally advanced unresectable or metastatic NETs or NECs.

Materials and methods: This study was a single-arm, retrospective clinical study conducted at Nanjing Drum Tower Hospital. Eligible for enrolment were patients with NET or NEC who had received surufatinib treatment. All patients were given surufatinib. Other concurrent treatment methods included immunotherapy, chemotherapy, and/or radiotherapy. The primary endpoint was the DCR evaluated by investigators according to RESIST v1.1. Secondary endpoints included ORR, PFS, OS and safety.

Conference:

Presenting Author:

Authors: Liu S, Zhang L, Liu B, Liu Q,

Keywords: neuroendocrine neoplasm, surufatinib, neuroendocrine carcinoma, neuroendocrine tumour, real-world study,